StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Amgen (AMGN) Announces New Data Evaluating Novel Investigational KRAS(G12C) Inhibitor in Larger Patient Group at WCLC
September 9, 2019 6:20 AM
(Updated - September 9, 2019 6:29 AM EDT)Amgen (NASDAQ: AMGN) today announced new data from the ongoing Phase 1 study ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot Corp. News
Hot FDA News
Management Comments
Next Articles
Baird Reiterates Neutral Rating on Amgen (AMGN)
September 9, 2019 8:26 AM
Cantor Fitzgerald Reiterates Neutral Rating on Amgen (AMGN)
September 9, 2019 7:03 AM
Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Larger Patient Group At WCLC 2019
September 8, 2019 3:45 AM